Saturday, October 3, 2026

Technology & Economy

3 articles

Graphic Design Job Postings Drop 57% Worldwide as AI Displaces Creative Work

Graphic Design Job Postings Drop 57% Worldwide as AI Displaces Creative Work

Graphic design job postings fell 57% globally over the past year, with product design roles down 18%. IDEO, the consultancy that shaped design thinking worldwide, saw revenue collapse from $300 million to under $100 million. AI tools including Midjourney, Adobe Firefly, and Figma AI are automating the volume work that once funded design firms across every major market.

LM Salvado•
One Taiwanese Foundry Stands Between Broadcom and $100 Billion in AI Revenue

One Taiwanese Foundry Stands Between Broadcom and $100 Billion in AI Revenue

Broadcom's CEO has forecast $100 billion or more in annual custom AI chip revenue by 2027 — all of it dependent on TSMC's Taiwan fabs. No rival foundry in South Korea, the US, or Europe matches TSMC's capability at scale. A Taiwan Strait disruption would halt that pipeline with no short-term alternative for Broadcom or its global cloud customers.

LM Salvado•
AI's Voracious Power Appetite Is Redrawing the Global Chip and Energy Map

AI's Voracious Power Appetite Is Redrawing the Global Chip and Energy Map

The artificial intelligence boom is generating an unprecedented demand for electricity that is reshaping semiconductor markets, data center infrastructure, and energy grids worldwide. Nations and corporations alike are racing to secure the power and silicon needed to compete in the AI era, concentrating capital in a handful of strategic chokepoints. The ripple effects extend from U.S. monetary policy to European energy planning and Asian chip supply chains.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com